XML 27 R12.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Expenses | 12 Months Ended
--- | ---
Jun. 30, 2022
Text block [abstract] |
Expenses | Note 7. Expenses
|  | Consolidated |
|  | 2022 |  |  | 2021 |  |  | 2020 |
|  | A$’000 |  |  | A$’000 |  |  | A$’000 |
Loss before income tax includes the following specific |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  |  |
EVT-801 program costs |  |  | 2,520 |  |  |  | 1,073 |  |  |  | — |
Cantrixil program costs |  |  | 12 |  |  |  | 429 |  |  |  | 1,673 |
Paxalisib program costs |  |  | 13,713 |  |  |  | 11,404 |  |  |  | 5,801 |
Employee benefits expense - salaries & wages and staff benefits |  |  | 1,664 |  |  |  | 336 |  |  |  | 861 |
- superannuation |  |  | 25 |  |  |  | 26 |  |  |  | 43 |
- share based payments |  |  | 365 |  |  |  | 8 |  |  |  | 32 |
Total research & development (excluding amortisation) |  |  | 18,299 |  |  |  | 13,276 |  |  |  | 8,410 |
Amortisation |  |  |  |  |  |  |  |  |  |  |  |
Paxalisib licensing agreement |  |  | 1,084 |  |  |  | 1,084 |  |  |  | 1,084 |
Evotech licensing agreement |  |  | 869 |  |  |  | 181 |  |  |  | — |
Total amortisation |  |  | 1,953 |  |  |  | 1,265 |  |  |  | 1,084 |
Total research & development |  |  | 20,252 |  |  |  | 14,541 |  |  |  | 9,494 |
Net foreign exchange loss |  |  |  |  |  |  |  |  |  |  |  |
Net foreign exchange loss |  |  | — |  |  |  | 430 |  |  |  | — |
Rental expense relating to operating leases |  |  |  |  |  |  |  |  |  |  |  |
Minimum lease payments |  |  | 73 |  |  |  | 93 |  |  |  | 108 |
Superannuation expense |  |  |  |  |  |  |  |  |  |  |  |
Defined contribution superannuation expense |  |  | 138 |  |  |  | 138 |  |  |  | 140 |
Employee benefits expense G&A |  |  |  |  |  |  |  |  |  |  |
- salaries & wages and staff benefits |  |  | 1,674 |  |  |  | 1,011 |  |  |  | 1,078 |
- superannuation |  |  | 129 |  |  |  | 112 |  |  |  | 96 |
- share based payments |  |  | 1,310 |  |  |  | 552 |  |  |  | 230 |
Total employee benefits expense G&A |  |  | 3,113 |  |  |  | 1,675 |  |  |  | 1,404 |
Other Expenses |  |  |  |  |  |  |  |  |  |  |  |
Chinese With-Holding Tax incurred on license transaction |  |  | — |  |  |  | 931 |  |  |  | — |
Chinese Value Added Tax incurred on license transaction |  |  | — |  |  |  | 538 |  |  |  | — |
|  |  | — |  |  |  | 1,469 |  |  |  | — |

X
- Definition The disclosure of expenses. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfExpensesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block [abstract] + References No definition available. + Details
Name: | kzia_TextBlockAbstract
Namespace Prefix: | kzia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration